{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:45Z","timestamp":1784139285609,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/md.0000000000002572","type":"journal-article","created":{"date-parts":[[2016,1,24]],"date-time":"2016-01-24T11:25:25Z","timestamp":1453634725000},"page":"e2572","source":"Crossref","is-referenced-by-count":21,"title":["Combination of Intravesical Chemotherapy and Bacillus Calmette\u2013Guerin Versus Bacillus Calmette\u2013Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"95","author":[{"given":"Jianfeng","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-55-20210309","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-55-20210309","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.juro.2007.09.082","article-title":"Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease","volume":"179","author":"Nieder","year":"2008","journal-title":"J Urol"},{"key":"R3-55-20210309","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"R4-55-20210309","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R5-55-20210309","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette\u2013Gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"R6-55-20210309","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance Bacillus Calmette\u2013Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent Tat1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"R7-55-20210309","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette\u2013Gu\u00e9rin, and Bacillus Calmette\u2013Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"R8-55-20210309","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU Guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"R9-55-20210309","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R10-55-20210309","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Stat Med"},{"key":"R11-55-20210309","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R12-55-20210309","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"R14-55-20210309","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"R15-55-20210309","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus bacillus Calmette\u2013Guerin (BCG) is more effective but more toxic than BCG alone in patients with nonmuscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial","volume":"67","author":"E","year":"2015","journal-title":"Eur Urol"},{"key":"R16-55-20210309","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"R17-55-20210309","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG Instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"R18-55-20210309","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","article-title":"Sequential intravesical combination therapy with mitomycin C and bacillus Calmette\u2013Gu\u00e9rin and with bacillus Calmette\u2013Gu\u00e9rin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"key":"R19-55-20210309","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1590\/S1677-55382012000400006","article-title":"The value of perioperative mitomycin C instillation in improving subsequent bacillus Calmette\u2013Guerin instillation efficacy in intermediate and high-risk patients with nonmuscle invasive bladder cancer: a prospective randomized study","volume":"38","author":"Gulpinar","year":"2012","journal-title":"Int Braz J Urol"},{"key":"R20-55-20210309","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can early single dose instillation of epirubicin improve bacillus Calmette\u2013Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"180","author":"Cai","year":"2008","journal-title":"J Urol"},{"key":"R21-55-20210309","first-page":"1310","article-title":"Sequential bacillus Calmette\u2013Guerin and epirubicin versus bacillus Calmette\u2013Guerin alone for superficial bladder tumors: a randomized prospective study","volume":"57","author":"Ali-El-Dein","year":"1999","journal-title":"J Urol"},{"key":"R22-55-20210309","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette\u2013Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"R23-55-20210309","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1464-410X.2012.11390.x","article-title":"Intravesical chemotherapy plus bacille Calmette\u2013Gu\u00e9rin in nonmuscle invasive bladder cancer: a systematic review with meta-analysis","volume":"111","author":"Houghton","year":"2012","journal-title":"Br J Urol Int"},{"key":"R24-55-20210309","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette\u2013Guerin for 3 years is not superior to standard induction therapy in high-risk nonmuscle-invasive urothelial bladder carcinoma: final results of randomised CUETO Study 98013","volume":"68","author":"Martinez-Pineiro","year":"2015","journal-title":"Eur Urol"},{"key":"R25-55-20210309","first-page":"1161","article-title":"EAU Recommendations 2001. \u201cGuidelines on bladder cancer\u201d","volume":"12","author":"Oosterlinck","year":"2002","journal-title":"Prog Urol"},{"key":"R26-55-20210309","first-page":"5890","article-title":"Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?","volume":"18","author":"Badalato","year":"2011","journal-title":"Can J Urol"},{"key":"R27-55-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:59:04Z","timestamp":1620961144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201601190-00055"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002572","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}